Streetbeat News

Products Services

AMRX

Amneal Pharmaceuticals has received FDA approval for its new Potassium Phosphates IV Infusion Bag, which is the first preservative-free single-dose presentation. This is the third 505(b)(2) injectable added by the company this year, and it will be launched in Q3.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:25 pm

IMNN

IMUNON, Inc. (NASDAQ:IMNN) will announce topline results from its Phase 2 OVATION 2 Study with IMNN-001 in advanced ovarian cancer on July 30 at 8:00 a.m. ET. A conference call to discuss the results will follow at 8:30 a.m. ET.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:25 pm

CLSD

Clearside Biomedical's partner, Arctic Vision, has reported positive Phase 3 results for ARCATUS in treating uveitic macular edema. Additionally, New Drug Applications (NDAs) for ARCATUS have been accepted in Australia and Singapore.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:24 pm

ATSG

BA

Air Transport Services Group, Inc. (ATSG) has delivered two Boeing 767-300 aircraft to Georgian Airways under multi-year leases. One aircraft is a passenger model delivered in June, and the other is a newly converted freighter delivered in July.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:14 pm

TTOO

T2 Biosystems has announced an exclusive distribution agreement in Malaysia and Indonesia for its T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel. This move follows their recent entry into Hong Kong and Macau, aiming to improve global sepsis care.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:12 pm

RMBS

Rambus has announced a new DDR5 client clock driver and SPD hub designed for high-performance desktops and notebooks. This new offering allows DIMMs to operate up to 7200 MT/s, catering to the demands of AI, gaming, and content creation.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:12 pm

CLDX

Celldex Therapeutics announced positive Phase 2 results for Barzolvolimab in treating Chronic Inducible Urticaria, achieving primary endpoints with significant complete response rates. The company plans to move forward with Phase 3 registration development.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:10 pm

VSTM

Verastem Oncology (NASDAQ: VSTM) has received FDA Orphan Drug Designation for its drugs avutometinib and defactinib for the treatment of pancreatic cancer. The company expects to report updated data from the ongoing RAMP 205 trial in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:08 pm

DXC

DXC Technology has successfully completed the rollout of an SAP Enterprise Resource Platform in a record six months, enabling Whitehaven Coal to double its size with successful implementation at Daunia and Blackwater mine sites.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:04 pm

CTEC

FSLR

ICLN

RAYS

TAN

VCLN

The Biden administration has doubled the U.S. tariff on Chinese solar panels to 50%, aiming to protect the domestic market from China's predatory behavior. First Solar's CEO, Mark Widmar, supports the move, emphasizing the need for a level playing field for U.S. manufacturers. The news comes ahead of First Solar's second-quarter earnings report. The tariff increase is seen as a measure to counteract China's oversupply of solar panels, which has been flooding international markets. The announcement has impacted the stock prices of First Solar and several clean energy ETFs.

Portfolio Pulse from Michael Juliano

July 29, 2024 | 8:03 pm